N
TXMD icon

Nuveen’s TherapeuticsMD TXMD Stock Holding History

Nuveen’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-21,234
Closed -$419K – 3483
2022
Q1 		$419K Hold
21,234
– – ﹤0.01% 3064
2021
Q4 		$411K Sell
21,234
-37,556
-64% -$1.13M ﹤0.01% 3117
2021
Q3 		$2.04M Sell
58,790
-20,467
-26% -$908K ﹤0.01% 2665
2021
Q2 		$4.72M Buy
79,257
+39,452
+99% +$2.39M ﹤0.01% 2282
2021
Q1 		$2.67M Sell
39,805
-520
-1% -$40.7K ﹤0.01% 2473
2020
Q4 		$2.44M Buy
40,325
+3,403
+9% +$232K ﹤0.01% 2411
2020
Q3 		$2.92M Sell
36,922
-1,097
-3% -$87.4K ﹤0.01% 2198
2020
Q2 		$2.38M Buy
38,019
+1,252
+3% +$72.9K ﹤0.01% 2262
2020
Q1 		$1.95M Buy
36,767
+10,563
+40% +$1.05M ﹤0.01% 2207
2019
Q4 		$3.17M Buy
26,204
+6,568
+33% +$944K ﹤0.01% 2224
2019
Q3 		$3.56M Buy
19,636
+2,573
+15% +$363K ﹤0.01% 2135
2019
Q2 		$2.22M Buy
+17,063
New +$3.06M ﹤0.01% 2384

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Nuveen's TXMD Position: Q2 2022 in Review

Nuveen sold out of TherapeuticsMD (TXMD) in Q2 2022, closing a stake of 21,234 shares — an estimated $419K sold.

Nuveen first reported a position in TXMD in Q2 2019 and held it in 12 quarters. The position peaked at $4.72M in Q2 2021. 53 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.

  • Nuveen reported no remaining TherapeuticsMD position as of Q2 2022 after selling out during the quarter.
  • Nuveen sold 21,234 TherapeuticsMD shares in Q2 2022, an estimated $419K.
  • Nuveen first reported a position in TherapeuticsMD in Q2 2019 and held it in 12 quarters.
  • Nuveen's TherapeuticsMD position peaked at $4.72M in Q2 2021.
  • 53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.

Based on Nuveen's 13F filing for Q2 2022, filed 15 Aug 2022.